KR970703428A - Hcmv 및 hsv로부터의 융합 당단백질(fusion glycoprotein from hcmv and hsv) - Google Patents
Hcmv 및 hsv로부터의 융합 당단백질(fusion glycoprotein from hcmv and hsv) Download PDFInfo
- Publication number
- KR970703428A KR970703428A KR1019960706516A KR19960706516A KR970703428A KR 970703428 A KR970703428 A KR 970703428A KR 1019960706516 A KR1019960706516 A KR 1019960706516A KR 19960706516 A KR19960706516 A KR 19960706516A KR 970703428 A KR970703428 A KR 970703428A
- Authority
- KR
- South Korea
- Prior art keywords
- protein
- hsv
- hcmv
- derivative
- vaccine
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title claims abstract description 11
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 6
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 6
- 230000004927 fusion Effects 0.000 title claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims abstract 6
- 102000037865 fusion proteins Human genes 0.000 claims abstract 6
- 102000004169 proteins and genes Human genes 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 229960005486 vaccine Drugs 0.000 claims 7
- 230000002163 immunogen Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims 1
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 239000013612 plasmid Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/035—Herpes simplex virus I or II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은, HSV의 당단백질 일부에 융합된 HCMV의 당단백질 일부를 포함하는 융합 단백질에 관한 것이다.
Description
HCMV 및 HSV로부터의 융합 당단백질(FUSION GLYCOPROTEIN FROM HCMV AND HSV)
[도면의 간단한 설명]
제1도는 카메라 gB의 구성 개요이다.
제2도는 pEE14-gB685**의 플라스미드 지도이다.
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (19)
- HCMV의 당단백질 부분이 HSV의 당단백질 부분에 융합되어 있는 것으로 이루어진 융합 단백질 또는 이들의 면역원성 유도체.
- 제1항에 있어서, HCMV의 gB 단백질 부분이 HSV의 gD 단백질 부분에 융합되어 있는 것으로 이루어지는 것을 특징으로 하는 단백질 또는 유도체.
- 제2항에 있어서, HCMV의 gB 단백질 일부의 N-말단 부분의 아미노산 및 HSV gD 단백질 일부의 C-말단의 아미노산 사이에서 상기 융합이 이루어지는 것을 특징으로 하는 단백질 또는 유도체.
- 제1항 내지 3항 중 어느 한 항에 있어서, HCMV 단백질 부분이 비-분해성인 것을 특징으로 하는 단백질.
- 제1항 내지 4항 중 어느 한 항에 있어서, HSV 단백질 부분이, gD2의 시그날 서열 및 gD의 아미노산 26 내지 52 및／또는 gD2로부터의 서열, 즉 PEDSALLEDPED을 포함하는 것을 특징으로 하는 단백질.
- 제1항 내지 5항 중 어느 한 항에 따른 융합 단백질 또는 이들의 면역원성 유도체를 코오드화하는 재조합 DNA.
- 매우 엄격한 조건(stringency)하에 제6항의 DNA와 혼성화되는 DNA.
- 제6항 또는 7항에 따른 재조합 DNA를 포함하는 발현 벡터.
- 제8항에 따른 벡터로 형질전환된 숙주.
- 약제학적으로 허용가능한 담체와의 혼합물로 제1항 내지 5항 중 어느 한 항에 따른 단백질 또는 이들의 면역원성 유도체를 포함하는 백신 조성물.
- HCMV 및 HSV에 대한 보호 반응을 가지는 융합 단백질을 포함하는 이중-기능 백신.
- 제11항에 있어서, HSV의 하나 이상의 하위 성분을 더 포함하는 것을 특징으로 하는 백신.
- 제10항 내지 12항 중 어느 한 항에 있어서, 3D 모노포스포릴 지질 A 및／또는 QS-21을 더 포함하는 것을 특징으로 하는 백신 조성물.
- 제10항 내지 13항 중 어느 한 항에 있어서, 상기 담체가 오일-인-물 에멀션인 것을 특징으로 하는 백신 조성물.
- 의약품에서 사용하기 위한 제1항 내지 5항 중 어느 한 항에 따른 융합 단백질 또는 이들의 면역원성 유도체.
- 의약품에서 사용하기 위한 제10항 내지 14항 중 어느 한 항에 따른 백신 조성물.
- 숙주 세포에서 상기 단백질을 코오드화하는 DNA 서열을 발현시키는 단계 및 상기 단백질을 회수하는 단계를 포함하는, 제1항 내지 5항 중 어느 한 항에 따른 융합 단백질의 제조 방법.
- 유효량의 제10항 내지 14항 중 어느 한 항에 따른 백신을 투여하는 단계를 포함하는, HCMV에 감염되기 쉬운 사람 또는 동물을 치료하는 방법.
- 바이러스 감염 치료에서 사용하기 위한 약제의 제조에서의 제1항 내지 5항 중 어느 한 항에 따른 단백질 또는 이들의 면역활성 유도체의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9409962A GB9409962D0 (en) | 1994-05-18 | 1994-05-18 | Novel compounds |
| GB9409962.9 | 1994-05-18 | ||
| PCT/EP1995/001800 WO1995031555A1 (en) | 1994-05-18 | 1995-05-11 | Fusion glycoprotein from hcmv and hsv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR970703428A true KR970703428A (ko) | 1997-07-03 |
Family
ID=10755348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960706516A KR970703428A (ko) | 1994-05-18 | 1995-05-11 | Hcmv 및 hsv로부터의 융합 당단백질(fusion glycoprotein from hcmv and hsv) |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US5889168A (ko) |
| EP (2) | EP0759995B1 (ko) |
| JP (1) | JPH10500009A (ko) |
| KR (1) | KR970703428A (ko) |
| AT (2) | ATE293697T1 (ko) |
| AU (1) | AU2527195A (ko) |
| BR (1) | BR9507728A (ko) |
| CA (1) | CA2190529A1 (ko) |
| CY (1) | CY2597B2 (ko) |
| DE (2) | DE69536112D1 (ko) |
| DK (1) | DK0759995T3 (ko) |
| ES (2) | ES2239758T3 (ko) |
| GB (1) | GB9409962D0 (ko) |
| HK (1) | HK1012415A1 (ko) |
| HU (1) | HU9603163D0 (ko) |
| NO (1) | NO964874D0 (ko) |
| PL (1) | PL317235A1 (ko) |
| PT (1) | PT759995E (ko) |
| SI (1) | SI0759995T1 (ko) |
| WO (1) | WO1995031555A1 (ko) |
| ZA (1) | ZA953961B (ko) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9409962D0 (en) * | 1994-05-18 | 1994-07-06 | Smithkline Beecham Biolog | Novel compounds |
| HUP0101047A3 (en) * | 1998-03-09 | 2004-10-28 | Smithkline Beecham Biolog | Combined vaccine compositions |
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| EP1811863B1 (en) * | 2004-10-22 | 2012-09-12 | Cargill, Incorporated | Process for the production of maltodextrins |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| MX2011006903A (es) | 2008-12-25 | 2011-09-15 | Chemo Sero Therapeut Res Inst | Vacuna recombinante de coriza infecciosa aviar y procedimiento para preparar la misma. |
| AU2010313339B2 (en) | 2009-10-30 | 2016-05-26 | The Administrators Of The Tulane Educational Fund | Peptide compositions and methods for inhibiting herpesvirus infection |
| AU2011315447A1 (en) | 2010-10-15 | 2013-05-09 | Glaxosmithkline Biologicals S.A. | Cytomegalovirus gB antigen |
| WO2015047901A1 (en) * | 2013-09-24 | 2015-04-02 | Duke University | Compositions, methods and kits for eliciting an immune response |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171568A (en) * | 1984-04-06 | 1992-12-15 | Chiron Corporation | Recombinant herpes simplex gb-gd vaccine |
| DE3751772T2 (de) * | 1986-10-20 | 1996-12-05 | Chiron Corp | Impfstoff zur behandlung von hsv |
| DE68929478T2 (de) * | 1988-01-29 | 2004-04-29 | Aventis Pasteur | Rekombinante CMV-Neutralisierungsproteine |
| GB9409962D0 (en) * | 1994-05-18 | 1994-07-06 | Smithkline Beecham Biolog | Novel compounds |
-
1994
- 1994-05-18 GB GB9409962A patent/GB9409962D0/en active Pending
-
1995
- 1995-05-11 JP JP7529352A patent/JPH10500009A/ja active Pending
- 1995-05-11 AT AT95919447T patent/ATE293697T1/de active
- 1995-05-11 HU HU9603163A patent/HU9603163D0/hu unknown
- 1995-05-11 ES ES95919447T patent/ES2239758T3/es not_active Expired - Lifetime
- 1995-05-11 SI SI9530717T patent/SI0759995T1/xx unknown
- 1995-05-11 DE DE69536112T patent/DE69536112D1/de not_active Expired - Lifetime
- 1995-05-11 US US08/737,691 patent/US5889168A/en not_active Expired - Lifetime
- 1995-05-11 DK DK95919447T patent/DK0759995T3/da active
- 1995-05-11 AT AT05075216T patent/ATE483809T1/de not_active IP Right Cessation
- 1995-05-11 CA CA002190529A patent/CA2190529A1/en not_active Abandoned
- 1995-05-11 EP EP95919447A patent/EP0759995B1/en not_active Expired - Lifetime
- 1995-05-11 PL PL95317235A patent/PL317235A1/xx unknown
- 1995-05-11 BR BR9507728A patent/BR9507728A/pt not_active Application Discontinuation
- 1995-05-11 PT PT95919447T patent/PT759995E/pt unknown
- 1995-05-11 DE DE69534162T patent/DE69534162T2/de not_active Expired - Lifetime
- 1995-05-11 AU AU25271/95A patent/AU2527195A/en not_active Abandoned
- 1995-05-11 ES ES05075216T patent/ES2353134T3/es not_active Expired - Lifetime
- 1995-05-11 KR KR1019960706516A patent/KR970703428A/ko not_active Application Discontinuation
- 1995-05-11 EP EP05075216A patent/EP1529845B1/en not_active Expired - Lifetime
- 1995-05-11 WO PCT/EP1995/001800 patent/WO1995031555A1/en active IP Right Grant
- 1995-05-16 ZA ZA953961A patent/ZA953961B/xx unknown
- 1995-05-18 US US08/443,642 patent/US5739292A/en not_active Expired - Lifetime
-
1996
- 1996-11-15 NO NO964874A patent/NO964874D0/no unknown
-
1997
- 1997-12-23 US US08/997,211 patent/US6036959A/en not_active Expired - Fee Related
-
1998
- 1998-12-15 HK HK98113484A patent/HK1012415A1/xx not_active IP Right Cessation
-
2006
- 2006-10-16 CY CY0600028A patent/CY2597B2/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0759995A1 (en) | 1997-03-05 |
| US6036959A (en) | 2000-03-14 |
| ZA953961B (en) | 1996-02-26 |
| PL317235A1 (en) | 1997-03-17 |
| ES2353134T3 (es) | 2011-02-25 |
| WO1995031555A1 (en) | 1995-11-23 |
| DE69534162T2 (de) | 2006-03-09 |
| NO964874L (no) | 1996-11-15 |
| EP1529845A2 (en) | 2005-05-11 |
| DE69534162D1 (de) | 2005-05-25 |
| ES2239758T3 (es) | 2005-10-01 |
| ATE483809T1 (de) | 2010-10-15 |
| PT759995E (pt) | 2005-07-29 |
| CY2597B2 (en) | 2010-03-03 |
| HU9603163D0 (en) | 1997-01-28 |
| JPH10500009A (ja) | 1998-01-06 |
| DE69536112D1 (de) | 2010-11-18 |
| US5889168A (en) | 1999-03-30 |
| CA2190529A1 (en) | 1995-11-23 |
| EP0759995B1 (en) | 2005-04-20 |
| GB9409962D0 (en) | 1994-07-06 |
| EP1529845A3 (en) | 2006-03-08 |
| SI0759995T1 (en) | 2005-10-31 |
| HK1012415A1 (en) | 1999-07-30 |
| BR9507728A (pt) | 1997-09-23 |
| AU2527195A (en) | 1995-12-05 |
| US5739292A (en) | 1998-04-14 |
| ATE293697T1 (de) | 2005-05-15 |
| NO964874D0 (no) | 1996-11-15 |
| DK0759995T3 (da) | 2005-08-01 |
| EP1529845B1 (en) | 2010-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4951196A (en) | Vaccines for plague | |
| DE69829668D1 (de) | Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe | |
| GB9224584D0 (en) | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases | |
| KR970703428A (ko) | Hcmv 및 hsv로부터의 융합 당단백질(fusion glycoprotein from hcmv and hsv) | |
| CA2193210A1 (en) | Method of inducing an immune response with a live venezuelan equine encephalitis virus expressing a heterologous immunogen | |
| CA2143845A1 (en) | Self-assembling recombinant papillomavirus capsid proteins | |
| EP0994724A4 (en) | METHODS AND COMPOSITIONS TO PREVENT THE REPRODUCTION OF HIV-1 | |
| RU2002113920A (ru) | Антигенные пептиды neisseria | |
| ATE321567T1 (de) | Rekombinante dimerische hüllproteine als impfstoff gegen eine flavivirale infektion | |
| US5843887A (en) | Compositions for delivery of polypeptides, and methods | |
| CN109715651A (zh) | 乙型肝炎治疗型疫苗 | |
| BR9812240A (pt) | Proteìna g alterada ou polipeptìdeo do rsv, uso da mesma, molécula de ácido nucleico codificando uma proteìna g alterada ou um polipeptìdeo do rsv, construção do ácido nucleico, célula hospedeira recombinante, processos de produção de uma proteìna g alterada ou polipeptìdeo do rsv composição imunogênica, de indução de uma resposta imune em um vertebrado, de inibir a indução do aumento da doença após a vacinação e subsequente infecção de um vertebrado com o rsv e de imunização de um vertebrado contra o rsv, composição de vacina, vacina, e, composição imunogênica | |
| ATE157258T1 (de) | Zubereitungen und behandlungen von pneumonia in tieren | |
| HUP9904171A2 (hu) | A ragadós száj- és körömfájás vírusok immunogén peptidjei | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| AU3379693A (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
| WO1997003187A3 (en) | Marek's disease virus genes and their use in vaccines for protection against marek's disease | |
| NZ507983A (en) | A polypeptide comprising the amino acid of an n- terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof | |
| KR960702000A (ko) | 귀밑샘염 바이러스로부터의 재조합 항원 및 백신에서의 이것의 사용방법(recombinant antigens from mumps virus and their use in vaccines) | |
| RU95113194A (ru) | Вакцины, способ получения, применение неинфекционных субвирусных частиц, векторы применение нуклеиновой кислоты | |
| DK0426314T3 (da) | HIV-relaterede peptider | |
| DK257887D0 (da) | Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden | |
| KR950701821A (ko) | 피임 백신(contraceptive vaccine) | |
| DE60022995D1 (de) | Impfstoff | |
| Dietzschold et al. | Synthesis of an antigenic determinant of the HSV gD that stimulates the induction of virus-neutralizing antibodies and confers protection against a lethal challenge of HSV. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |